Pfizer launches new biopharmaceutical company to develop Parkinson’s drugs

News

Author: Simge Eva DoganPublished: 7 November 2018

Prep: Cook: Serves:

Pharmaceutical company Pfizer has teamed with investment firm Bain Capital to launch Cerevel Therapeutics – a biopharmaceutical company focused on developing drugs for Parkinson’s and other central nervous system conditions.

The new company – which will receive US $350 million of investment from Bain Capital – will begin working on phase three clinical trials on a Parkinson’s drug designed to increase levels of dopamine in the brain. Cerevel will also continue to develop several of Pfizer’s drug programmes which closed earlier this year.

Marco Baptista, director of research programmes at The Michael J Fox Foundation – which has partnered with Pfizer since 2010 – said: “This is welcome news for Parkinson’s patients and researchers. Pfizer had developed a diverse group of novel therapeutics for Parkinson’s disease, which are now going to get another chance at success. MJFF looks forward to partnering with Cerevel to support the advancement of these promising programs.”

To read more on this topic click here.

For more information on Parkinson’s treatments please visit the EPDA website

New smart glasses could track Parkinson’s symptoms

Last Month

Next Month

Go Back

Share this story

Comments

Europe

Leading MEP declares Parkinson’s “a European priority issue”

Campaigners advocate for better EU policy towards Parkinson’s

PD in Practice

“Telemedicine has the potential to take a great deal of burden off patients and families”

A neurologist and a person with Parkinson’s disease talk remote care

Quinoa risotto with a ‘forestière’ mushroom sauce

Swap rice for superfood quinoa in this wild mushroom risotto

A “revolutionary” step in stem cell therapy for Parkinson’s disease?

Scientists in China have developed a method to help improve stem cell research in mice models of Parkinson’s – which could potentially lead to promising new treatments. The researchers, based at the Chinese Academy of Sciences, identified two cell surface markers of dopamine neurons, which are reduced in Parkinson’s. They injected cells with these markers into the brains of the mice and found that this resulted in “higher therapeutic potency” for improving motor symptoms of the condition. As part of their research, the team also worked to control the variability of donor cells, to help improve therapeutic outcomes for Parkinson’s cell therapy. The researchers, whose study was published in ‘The Journal of Clinical Investigation’, described the findings as a “revolutionary step on the road towards more effective and safer stem cell therapies”.

Could frequent nightmares be an early sign of Parkinson’s disease?

A new study has suggested that experiencing recurrent nightmares and bad dreams could be an early symptom of Parkinson’s disease. Researchers from the University of Birmingham, UK, used data from an existing US study that followed 3818 men, aged 67 or older, over a period of 12 years. Participants who reported experiencing bad dreams at least once a week were followed up. During the follow up, 91 people were diagnosed with Parkinson’s. The results suggested that participants who had frequent bad dreams were twice as likely to develop the condition as those who did not. Commenting on the study, lead author Dr Abidemi Otaiku said: “While we need to carry out further research, identifying the significance of bad dreams and nightmares could indicate that individuals who experience changes to their dreams in older age – without any obvious trigger – should seek medical advice.”

More than £2m awarded to research on mitochondria and Parkinson’s disease

Researchers at UK biotech startup NRG Therapeutics are developing potential treatments that may help slow the progression of Parkinson’s by protecting the mitochondria – a part of every human cell that works to power chemical reactions. The company has now received a £2.68m award from government-backed agency Innovate UK to continue its research. Their research built upon previous findings that damage to mitochondria in the substantia nigra – an area of the brain associated with dopamine – may be linked to Parkinson’s. The scientists developed molecules that keep a ‘pore’ in the mitochondria closed, which stops calcium flowing into it, preventing a process that eventually ruptures the powerhouse of the cell and leads to its death. The new funding award follows previous investment from Parkinson’s UK and the Michael J Fox Foundation.

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Email
This field is for validation purposes and should be left unchanged.

Pfizer launches new biopharmaceutical company to develop Parkinson’s drugs

News

Author: Simge Eva DoganPublished: 7 November 2018

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Europe

Leading MEP declares Parkinson’s “a European priority issue”

sponsored article

PD in Practice

“Telemedicine has the potential to take a great deal of burden off patients and families”

Recipes & Nutrition

Quinoa risotto with a ‘forestière’ mushroom sauce

A “revolutionary” step in stem cell therapy for Parkinson’s disease?

Could frequent nightmares be an early sign of Parkinson’s disease?

More than £2m awarded to research on mitochondria and Parkinson’s disease

{title}

Subscribe

Pfizer launches new biopharmaceutical company to develop Parkinson’s drugs

News

Author: Simge Eva DoganPublished: 7 November 2018

Last Month

Next Month

Share this story

Comments

Related articles

Europe

Leading MEP declares Parkinson’s “a European priority issue”

sponsored article

PD in Practice

“Telemedicine has the potential to take a great deal of burden off patients and families”

Recipes & Nutrition

Quinoa risotto with a ‘forestière’ mushroom sauce

A “revolutionary” step in stem cell therapy for Parkinson’s disease?

Could frequent nightmares be an early sign of Parkinson’s disease?

More than £2m awarded to research on mitochondria and Parkinson’s disease

{title}

Subscribe

Sign in